ENDPOINTS

AnaptysBio describes ‘JAK-like’ efficacy for PD-1 drug in rheumatoid arthritis

AnaptysBio is claiming success with longer follow-up data from a Phase 2b trial in rheumatoid arthritis as it looks for a partner to take its PD-1 drug into Phase 3. Back in February, the company ...

Jun 4, 2025 - 16:24
 0
AnaptysBio describes ‘JAK-like’ efficacy for PD-1 drug in rheumatoid arthritis
AnaptysBio is claiming success with longer follow-up data from a Phase 2b trial in rheumatoid arthritis as it looks for a partner to take its PD-1 drug into Phase 3. Back in February, the company ...
Read More

Tags:

Previous Article

Wild cockatoos are learning how to use water fountains

Next Article

Cognixion, Pupil Labs partner on eye-tracking interface

Related Posts

Regeneron makes $80M obesity deal with Hansoh

Regeneron makes $80M obesity deal with Hansoh

Jun 2, 2025  0

Gilgamesh’s psychedelic shows rapid effect in depression study

Gilgamesh’s psychedelic shows rapid effect in depressio...

May 27, 2025  0

How PureTech’s lung fibrosis drug stacks up against the competition

How PureTech’s lung fibrosis drug stacks up against the...

May 21, 2025  0